Clinical Trials Browser

Glioblastoma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT02830724 2026-04-06

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

Phase 1/2 Recruiting

124 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

Phase 1/2 Completed

224 enrolled 15 charts

Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

NCT05922930 2026-02-19

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

Phase 1/2 Recruiting

51 enrolled

GastrointestinalGynecologic

Adenocarcinoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT07410494 2026-02-18

SELECT-CAR-NK

Phase 1/2 Recruiting

85 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Liver Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT05357027 2026-01-21

HPV16 E6 TCR T Cells for Cervical Carcinoma

Phase 1/2 Terminated

5 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT03907852 2025-08-27

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Phase 1/2 Active not recruiting

57 enrolled

GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Cholangiocarcinoma

NCT05451849 2025-08-27

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Phase 1/2 Active not recruiting

6 enrolled

BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT06505551 2024-07-17

Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma

Phase 1/2 Not yet recruiting

66 enrolled

GastrointestinalGenitourinaryGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT03287674 2023-03-01

TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer

Phase 1/2 Completed

7 enrolled 10 charts

Gynecologic

Ovarian Neoplasms

NCT02111850 2022-03-29

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive

Phase 1/2 Completed

21 enrolled 22 charts

BreastDermatologicGenitourinaryGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma

NCT04389229 2020-12-16

OVSTAR

Phase 1/2 Withdrawn

Gynecologic

Ovarian Cancer Metastatic

NCT01583686 2019-10-14

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

Phase 1/2 Terminated

15 enrolled 14 charts

GastrointestinalGynecologicOther solid neoplasmThoracic

Uterine Cervical Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT02153905 2019-06-17

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

Phase 1/2 Terminated

3 enrolled 14 charts

BreastDermatologicGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis

NCT03916679 2019-04-16

MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer

Phase 1/2 Unknown

20 enrolled

Gynecologic

Ovarian Neoplasms, Recurrence

NCT02280811 2017-09-06

T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers

Phase 1/2 Completed

12 enrolled 19 charts

GastrointestinalGenitourinaryGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms

Clinical Trials

SELECT-2CAR

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

SELECT-CAR-NK

HPV16 E6 TCR T Cells for Cervical Carcinoma

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma

TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive

OVSTAR

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer

T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers